Brief: Hookipa Pharma Presents Additional Preliminary Phase 2 Data On HB-200

Hookipa Pharma

22/10/2023 11:04

Oct 22 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA PHARMA PRESENTS ADDITIONAL PRELIMINARY PHASE 2
DATA ON
HB-200 IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT
IN PATIENTS WITH HPV16+ HEAD AND NECK CANCERS AT EUROPEAN
SOCIETY FOR MEDICAL ONCOLOGY CONGRESS 2023
    * HOOKIPA PHARMA  - 42 PERCENT OBJECTIVE RESPONSE RATE WAS
OBSERVED AMONG 19 EVALUABLE PATIENTSWITH RECURRENT/METASTATIC
HEAD AND NECK CANCER IN FIRST-LINE SETTING-DOUBLING HISTORICAL
ORR REPORTED WITH PEMBROLIZUMAB ALONE
    * STRONG IMMUNOGENICITY AND ACTIVATION OF ANTIGEN-SPECIFIC
CD8+ T
CELLS OBSERVED
    * HOOKIPA PHARMA  - DATA REINFORCE HOOKIPA'S COMMITMENT TO
START A
RANDOMIZED TRIAL OF HB-200 IN COMBINATION WITH PEMBROLIZUMAB AS
1ST-LINE TREATMENT OF RECURRENT/METASTATIC HPV16+ HEAD AND NECK
CANCER IN 2024

Source text for Eikon:  ID:nGNX7N6pxp 
Further company coverage:  HOOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))